Ibudilast in the Treatment of Patients With Chronic Migraine. (IBU-003)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This will be a double-blind, randomised, placebo-controlled, two period cross over study of ibudilast in the treatment of chronic migraine. The study will involve a screening visit followed by eight visits to the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH), for baseline testing, initiation of the study medications and ongoing data collection (one baseline and three study visits during each treatment period). At the baseline visit, blood samples to assess biomarkers (glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100β) will be taken. Patients will then be randomised (in a 1:1 ratio) to commence either ibudilast or placebo treatment, which will continue for 8 weeks. Subsequently participants will undergo a 4-week washout period. At the end of the washout period a second 8-week treatment block with the alternative treatment will commence.
Patients will complete a headache diary daily for at least 4 weeks prior to the baseline visit, throughout the treatment and washout periods and for 4 weeks after treatment ceases. The diary will record headache frequency, duration, intensity, pain characteristics and medication intake for comparison with baseline data.
From screening until the final study visit (over a minimum of 6 months) a total of approximately 200 mL in blood samples will be taken from each participant.
- We hypothesise ibudilast will be an effective treatment for chronic migraine, reducing number of moderate to severe headache days per month.
- We hypothesise serum levels of glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100 calcium binding protein β will be able to differentiate response to treatment with ibudilast.
- We hypothesise ibudilast dosed at 40 mg twice daily for 8 weeks will be safe and well tolerated.
| Condition | Intervention | Phase |
|---|---|---|
|
Migraine Headache |
Drug: Ibudilast Drug: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST |
- Primary efficacy end point [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
As suggested by the IHS guidelines for clinical trials in chronic migraine, the primary efficacy endpoint will be number of headache days per month with moderate or severe intensity. Study outcomes will be assessed at baseline and at weeks 2, 4 and 8 of each treatment period.
To monitor treatment with ibudilast, blood biochemistry (including assessment of renal and hepatic including GGT function) and haematology will be assessed at baseline, and at weeks 2, 4 and 8 of each treatment period. Patients will also be screened for adverse effects via questionnaire at each visit during treatment.
- Secondary efficacy end points [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
The secondary end points assessed will include:
- Migraine frequency (number of days with migraine of any severity/month)
- Migraine episode frequency (number of migraine episodes/month)
- Medication frequency (number of days acute headache medication taken/month)
- Headache related impact on quality of life as assessed using the HIT-6
- Cutaneous allodynia as assessed using the ASC-12
- Biomarker levels
- Serum biomarker levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]To determine if serum levels of the following potential biomarkers are able to differentiate response to treatment with ibudilast: glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100 calcium binding protein β.
- safety and tolerability of ibudilast [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]Ibudilast 40 mg or placebo twice daily for 8 weeks is effective and safe in a chronic migraine population.
| Estimated Enrollment: | 42 |
| Study Start Date: | June 2013 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Ibudilast |
Drug: Ibudilast
Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
Other Name: Ibudilast (Pinatos® 10 mg capsules) manufactured by Taisho Pharmaceutical Industries Ltd., supplied by MediciNova
|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Other Name: Placebo capsules manufactured by Taisho Pharmaceuticals and are identical in appearance to Pinatos®
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Men and women aged between 18 to 65 years Migraine with or without aura, as diagnosed according to the second edition International Classification of Headache Disorders (ICHD-II) Onset of migraine before 50 years of age Headache on 15 or more days per month Migraine-like headache on 8 or more days per month, as per the IHS guidelines
Exclusion Criteria:
- Change in type or dose of migraine prophylactic medication in last 3 months
- Medication overuse headache as diagnosed according to the ICHD-IIR
- Post-traumatic headache as diagnosed according to the ICHD-II
- Other dominant chronic pain condition
- Known active inflammatory diseases such as rheumatoid arthritis
- History of recent cerebrovascular disorder
- Unable to provide written informed consent
- Unable to read and write in English
- Severe psychological/psychiatric disorders
- Recent history of significant trauma, as determined by the Principal Investigator including major surgery within the previous 2 months or major surgery planned during the treatment period
- Recent history of drug or alcohol abuse
- Any clinically significant findings on screening blood sample results
- Current malignancy
- Known hypersensitivity to ibudilast or excipients in Pinatos® formulation
- Renal or hepatic impairment, defined as baseline GFR (as calculated by the Cockcroft-Gault equation) of <60 mL/min, LFTs (excluding bilirubin) > 3 times the upper limit of normal or bilirubin > 2 times the upper limit of normal
For females of childbearing potential:
- Pregnancy
- Lack of adequate contraception (abstinence, double barrier method, intrauterine device, surgical sterilization (self or partner), hormonal contraceptive methods (oral, injected, or implanted)
- Breastfeeding
Contacts and Locations| Contact: Paul Rolan, MBBS FRACP FFPM MD | +61 8 8303 4102 | paul.rolan@adelaide.edu.au |
| Australia | |
| School of Medical sciences, University of Adelaide | Not yet recruiting |
| Adelaide, Australia | |
| Contact: Paul Rolan, MBBS FRACP FFPM MD paul.rolan@adelaide.edu.au | |
| Contact: Parisa Gazerani, Pharm D, PhD gazerani@hst.aau.dk | |
| Sub-Investigator: Parisa Gazerani, Pharm D, PhD | |
| Principal Investigator: Paul Rolan, MBBS FRACP FFPM MD | |
| Principal Investigator: | Paul Rolan, MBBS FRACP FFPM MD | School of Medical sciences, University of Adelaide, Adelaide, Australia |
| Principal Investigator: | Parisa Gazerani, PharmD, PhD | Aalborg University |
More Information
No publications provided
| Responsible Party: | Parisa Gazerani, Associtae professor, Aalborg University |
| ClinicalTrials.gov Identifier: | NCT01389193 History of Changes |
| Other Study ID Numbers: | IBU-003, MRF and DRC |
| Study First Received: | June 29, 2011 |
| Last Updated: | February 25, 2013 |
| Health Authority: | Australia: Human Research Ethics Committee The Human Research Ethics Committee of the Royal Adelaide Hospital: Australia |
Keywords provided by Aalborg University:
|
ibudilast migraine glial cell |
Additional relevant MeSH terms:
|
Headache Migraine Disorders Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Ibudilast Bronchodilator Agents Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Hematologic Agents Vasodilator Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 16, 2013